Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

TAEST16001

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Athenex, Guangzhou Xiangxue Pharma

Drug class:

TCR modulator, NY ESO 1 inhibitor

Related drugs:

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

afamitresgene autoleucel (3)

FH-TCR-Tᴍsʟɴ (0)

HA-1 T TCR T Cell Immunotherapy (0)

MAGE A3 TCR (0)

NY-ESO-1 TCR (0)

NY-ESO-1 TCR-T cell therapy (0)

T-Plex-200-A0201/204-A0201 (0)

T-cell receptor therapy (0)

TSC-200-A0201 (0)

TSC-204-A0201 (0)

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

›

HLA-A*02:01	Soft Tissue Sarcoma	HLA-A*02:01	Soft Tissue Sarcoma	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2	TAEST16001 Sensitive: C2 – Inclusion Criteria TAEST16001 Sensitive : C2
HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	HLA-A*02:01 + CTAG1B expression	Soft Tissue Sarcoma	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3	TAEST16001 Sensitive: C3 – Early Trials TAEST16001 Sensitive : C3